Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.

Abstract: A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen-presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject.

Abstract: Methods and compositions are provided for inhibiting or treating a herpesvirus infection in a subject using inhibitors of mammalian Akt.

Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carriers with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., through a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.

Abstract: Methods are provided for producing differentiated cells from stem cells, including producing hepatocytes. Compositions thereof are also provided, as are methods of treating a liver disorder.

Abstract: Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.

Abstract: Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.

Abstract: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.

Abstract: Aptamers targeted to a human transferrin receptor which do not compete with transferrin for binding are provided. Compositions and methods for aptamer-targeted liposomal drug delivery are also provided.

Abstract: Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2.

Abstract: Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin: total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.

Abstract: Methods are provided for labeling and for detecting DNA-interacting proteins with an assayable label, comprising combining the DNA-interacting protein with a mfpA pentapeptide repeat family protein that has been purified and that binds to the protein, wherein the mfpA pentapeptide repeat family protein is bound to an assayable label.

Abstract: Methods and kits are provided for testing the functional effect of methylating different cytosine residues, for testing patterns of DNA methylation on gene expression, and for site-specific methylation, as well as methylated DNA constructs. Methods are provided that include steps of denaturing a circular double-stranded DNA construct; hybridizing primers to separate strands of the denatured circular DNA construct; contacting the hybridized primers with a DNA polymerase, deoxynucleoside triphosphates, and copies of the primers; contacting nicked copies with a DNA ligase so as to form a copy of the circular DNA construct; contacting the copy of the circular DNA construct with a methyltransferase enzyme; transfecting a cell with C-5 methylated circular DNA construct; and quantifying expression of a gene of interest, thereby determining the effect of C-5 methylating cytosine nucleotide residues of DNA on expression of the gene of interest.

Abstract: Methods and compositions are provided for treating HIV infection and for inhibiting HIV infection, and for identifying purinergic receptor antagonists or Panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject having an HIV infection, or suspected of having been exposed to HIV, comprising administering to the mammalian subject an amount of (i) an antagonist of a Panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) HIV fusion with a target cell, or (b) HIV replication, or (c) HIV entry into a target cell, or two or more of (a), (b) and (c).

Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.

Abstract: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.

Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.

Abstract: The invention relates to the treatment of cancer using an inhibitor of 5?-methylthioadenosine phosphorylase (MTAP). The invention particularly relates to the treatment of prostate cancer and head and neck cancer.

Abstract: The present invention provides methods of inhibiting angiogenesis in a malignant tumor, inhibiting metastasis of a malignant tumor and of inhibiting transformation of a benign tumor to a malignant tumor. The present invention also provides assays for identifying inhibitors of angiogenesis in a malignant tumor, inhibitors of metastasis of a malignant tumor and of inhibitors of transformation of a benign tumor to a malignant tumor.

Abstract: Methods are provided for detecting mycobacteria in a sample, including clinical samples. Methods are also provided for determining susceptibility of mycobacterial strains to known or potential antibiotic agents, as are kits therefor. Recombinant mycobacteriophages are also provided comprising heterologous nucleic acids of interest.